title: Using genetic testing to guide warfarin therapy.
authors.affiliation: Mayo Clinic in Rochester, MN, USA.
authors.forename: Lisa L
authors.initials: LL
authors.lastname: Ungerer
authors.forename: Elizabeth L
authors.initials: EL
authors.lastname: Pestka
authors.forename: Penny K
authors.initials: PK
authors.lastname: Messner
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065729:Cytochrome P-450 CYP2C9; D004305:Dose-Response Relationship, Drug; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D006801:Humans; D006899:Mixed Function Oxygenases / Q000235:genetics*; D064417:Vitamin K Epoxide Reductases; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D014859:Warfarin; D006899:Mixed Function Oxygenases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D064417:Vitamin K Epoxide Reductases